DGAP-Adhoc: Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover
Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH
15-Dec-2021 / 13:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation - MAR)
Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH
Grünwald, December 15, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), through Dermapharm AG, today entered into an agreement with Canopy Growth Germany GmbH, based in St. Leon-Rot, Germany, to acquire C³ Cannabinoid Compound GmbH, based in Neumarkt, Germany, and its subsidiaries Spectrum Therapeutics GmbH, based in Neumarkt, Germany, THC Pharm GmbH The Health Concept, based in Frankfurt, Germany, and Spectrum Therapeutics Austria GmbH, based in Vienna, Austria. Upon completion of the transaction, Dermapharm AG will acquire 100.00 percent of the shares in the company, which specializes in the development, production and marketing of natural and synthetic active pharmaceutical ingredients based on cannabinoids. The purchase price is in the order of EUR 80 million plus possible performance-based limited purchase price components.
The closing of the transaction is subject to the approval of the antitrust authorities. The Management Board expects the transaction to be completed by the end of January 2022.
>End of the Ad hoc announcement<
Contact
Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
E-Mail: [email protected]
15-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Dermapharm Holding SE |
|
Lil-Dagover-Ring 7 |
|
82031 Grünwald |
|
Germany |
Phone: |
+49 (0)89 64 86-0 |
E-mail: |
[email protected] |
Internet: |
ir.dermapharm.de |
ISIN: |
DE000A2GS5D8 |
WKN: |
A2GS5D |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: |
1258267 |
|
End of Announcement |
DGAP News Service |
1258267 15-Dec-2021 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
467,12 |
572,42 |
700,88 |
793,83 |
942,91 |
1.024,78 |
1.135,35 |
EBITDA1,2 |
108,60 |
139,63 |
168,53 |
184,52 |
354,07 |
344,87 |
287,48 |
EBITDA-Marge3 |
23,25 |
24,39 |
24,05 |
23,24 |
37,55 |
33,65 |
|
EBIT1,4 |
92,12 |
107,51 |
119,51 |
136,85 |
298,47 |
243,69 |
182,89 |
EBIT-Marge5 |
19,72 |
18,78 |
17,05 |
17,24 |
31,65 |
23,78 |
16,11 |
Jahresüberschuss1 |
77,74 |
75,23 |
77,81 |
85,93 |
208,90 |
132,62 |
60,53 |
Netto-Marge6 |
16,64 |
13,14 |
11,10 |
10,82 |
22,16 |
12,94 |
5,33 |
Cashflow1,7 |
86,74 |
159,13 |
100,61 |
131,10 |
250,37 |
288,53 |
219,42 |
Ergebnis je Aktie8 |
1,56 |
1,41 |
1,43 |
1,59 |
3,89 |
2,49 |
1,16 |
Dividende8 |
0,00 |
0,77 |
0,80 |
0,88 |
2,17 |
1,05 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Grant Thornton
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Dermapharm Holding |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2GS5D |
32,500 |
Halten |
1.749,80 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
14,13 |
24,42 |
0,58 |
18,07 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,56 |
7,97 |
1,54 |
9,35 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,05 |
0,88 |
2,71 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
15.05.2024 |
27.08.2024 |
14.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-9,57% |
-18,03% |
-23,24% |
-28,35% |
|
|